GSK (LON:GSK – Get Free Report)‘s stock had its “buy” rating reaffirmed by Citigroup in a research note issued to investors on Monday, MarketBeat Ratings reports. They presently have a GBX 2,100 ($26.64) target price on the stock. Citigroup’s price objective suggests a potential upside of 31.66% from the stock’s current price.
GSK has been the topic of a number of other research reports. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research report on Tuesday, June 18th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 ($24.74) price target on shares of GSK in a research note on Tuesday, June 18th. Shore Capital reiterated a “buy” rating on shares of GSK in a research note on Wednesday, June 12th. Finally, Barclays reiterated an “equal weight” rating and issued a GBX 1,725 ($21.88) price target on shares of GSK in a research note on Tuesday, May 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, GSK presently has a consensus rating of “Hold” and a consensus target price of GBX 1,725.63 ($21.89).
GSK Price Performance
Insider Transactions at GSK
In related news, insider Wendy Becker purchased 446 shares of the stock in a transaction dated Thursday, June 20th. The stock was bought at an average cost of GBX 1,614 ($20.47) per share, for a total transaction of £7,198.44 ($9,131.60). Company insiders own 1.60% of the company’s stock.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
- Five stocks we like better than GSK
- What is a Low P/E Ratio and What Does it Tell Investors?
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- Stock Market Upgrades: What Are They?
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.